ZIG
KROS icon

Zullo Investment Group’s Keros Therapeutics KROS Stock Holding History

Zullo Investment Group’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-300
Closed -$14.4K – 453
2022
Q4 		$14.4K Hold
300
– – 0.01% 437
2022
Q3 		$11K Hold
300
– – 0.01% 470
2022
Q2 		$8K Hold
300
– – 0.01% 534
2022
Q1 		$16K Hold
300
– – 0.01% 462
2021
Q4 		$18K Buy
+300
New +$15K 0.01% 443

Other funds holding KROS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Zullo Investment Group's KROS Position: Q1 2023 in Review

Zullo Investment Group sold out of Keros Therapeutics (KROS) in Q1 2023, closing a stake of 300 shares — an estimated $14.4K sold.

Zullo Investment Group first reported a position in KROS in Q4 2021 and held it in 5 quarters. The position peaked at $18K in Q4 2021. 129 funds tracked by Wall St. Rank hold KROS as of Q1 2023.

  • Zullo Investment Group reported no remaining Keros Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Zullo Investment Group sold 300 Keros Therapeutics shares in Q1 2023, an estimated $14.4K.
  • Zullo Investment Group first reported a position in Keros Therapeutics in Q4 2021 and held it in 5 quarters.
  • Zullo Investment Group's Keros Therapeutics position peaked at $18K in Q4 2021.
  • 129 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2023.

Based on Zullo Investment Group's 13F filing for Q1 2023, filed 25 Apr 2023.